Drug intelligence / Profile preview

XM003

Development stage: Preclinical
Lead developer: Hefei Xingmou Biotechnology
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Gene Therapies
Administration: Ophthalmic

Overview

XM003 is an investigational drug candidate being developed by Hefei Xingmou Biotechnology (also known as StarryGene) for the treatment of thyroid eye disease (Graves' ophthalmopathy). As of early 2024, the program is in the IND-enabling phase, with plans to initiate an investigator-initiated trial (IIT) in the third quarter of 2025. Hefei Xingmou Biotechnology specializes in advanced technology platforms including AAV-based gene therapy and mRNA-encoded biologics for ophthalmic and metabolic conditions; however, the specific molecular target and modality for XM003 have not been publicly disclosed.

Beyond the preview

Go deeper on XM003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on XM003.

Explore the full profile